Open AccessDifferentiation therapy: a promising strategy for cancer treatment
Author(s) -
Yan Min,
Liu Quentin
Publication year - 2016
Publication title -
cancer communications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.119
H-Index - 53
ISSN - 2523-3548
DOI - 10.1186/s40880-015-0059-x
Subject(s) - ezh2 , cancer research , nasopharyngeal carcinoma , cancer , differentiation therapy , enhancer , kinase , cancer therapy , medicine , biology , radiation therapy , epigenetics , microbiology and biotechnology , genetics , transcription factor , gene , acute promyelocytic leukemia , retinoic acid
Poor differentiation is an important hallmark of cancer cells, and differentiation therapy holds great promise for cancer treatment. The restoration of IkB kinase α (IKKα) leads to the differentiation of nasopharyngeal carcinoma cells with reduced tumorigenicity. The findings by Yan et al. validate the polycomb protein enhancer of zeste homologue 2 (EZH2) as a target for intervention.